July 26, 2011 – According to the 2011 Top 20 Best in KLAS Awards: Medical Equipment & Infrastructure report, GE Healthcare’s Logiq E9 has been recognized as the top general imaging ultrasound system in the market. In the same report, GE’s Vivid E9 was awarded a share of the top spot for cardiovascular ultrasound systems.

July 26, 2011 – Cardio Pulmonary Diagnostic LLC in Newark and Hudson County Cardiovascular Care PC in Jersey City, N.J. have selected McKesson’s Practice Complete certified electronic health record (EHR) and practice management system. Built with cloud-computing technology, the integrated solution is designed to help providers improve billing and patient services, assist in accelerating payments and contribute to reductions in information technology costs and regulatory risk.

July 26, 2011 – The Resolute drug-eluting stent (DES) from Medtronic Inc. showed superiority to Boston Scientific Corp.’s Taxus DES on in-stent late lumen loss at eight months, the primary endpoint of the RESOLUTE Japan clinical study.

July 25, 2011 — Cardiac Science Corp., manufacturer of automated external defibrillators (AEDs) and diagnostic cardiac monitoring devices, announced the new capability of direct communication between its HeartCentrix connectivity solution and the GE Healthcare Centricity EMR system.

The U.S. Food and Drug Administration (FDA) said it is amending the classification regulation for electrocardiograph (ECG) electrodes into a class II device category, exempting these devices from FDA clearances. This rule is effective as of Aug. 22, 2011.

July 21, 2011 – Concentric Medical Inc. announced the launch of the expanded family of Merci Retrievers in Japan for the treatment of ischemic stroke. With the addition of the V 2.0 Soft and V 3.0 Soft, through recent Ichihen Approval, the entire family of V Series Merci Retrievers are now approved and reimbursed in Japan. The Merci Retriever is a catheter-based medical device that stroke centers use to remove blood clots from the brains of patients suffering an ischemic stroke.

July 20, 2011 — IDEV Technologies Inc. announced the completion of enrollment in the SUPERB trial, a U.S. Food and Drug Administration (FDA)-approved IDE trial evaluating the use of IDEV's Supera stent system for treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA). Enrollment was completed in May, making SUPERB one of the fastest-enrolling SFA trials.